Puma Biotechnology Inc (PBYI) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Puma Biotechnology Inc   (NASDAQ: PBYI)


Puma Biotechnology Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Puma Biotechnology Inc 's ROA in the second quarter of 2026?
Puma Biotechnology Inc achieved a return on average assets (ROA) of 12.5 % in its second quarter of 2026, this is above PBYI's average return on assets of -48.98%.
Puma Biotechnology Inc assets over the 12 months ending in its second quarter of 2026 are valued at $214 million

ROA has improved compared to 12.09% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 73 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 397 to 488.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 24.57 % -1.77 % 1.39 % -8.09 % -4.92 %
Y / Y Net Income Change 39.86 % - -30.39 % -56.47 % -
Net Income (TTM) in million 27 24 31 37 48
Return On Assets (TTM) 12.5 % 12.09 % 15.36 % 18.32 % 23.49 %
PBYI's Total Ranking # 488 # 397 # 272 # 193 # 269
Total Assets (TTM) in million 243 193 216 203 195
Seq. Total Assets Change 26 % -10.91 % 6.63 % 4.08 % -0.64 %
Seq. Net Income Change - - 51.94 % 51.05 % 96.87 %

PBYI's 5 Years Annual ROA >> Back to PBYI Management Effectiveness >> Compare PBYI ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 31
Sector # 74
Overall # 423

Return On Assets Statistics
High Average Low
23.49 %
-48.98 %
-158.49 %
(Jun 30 2025)   (Dec 31 2017)





Financial Statements
Puma Biotechnology Inc 's Assets $ 243 million PBYI's Balance sheet
Puma Biotechnology Inc 's Income $ 8 million Quarterly PBYI's Income Statement
PBYI's Income by Division See PBYI's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 1.39 % 7.08 % -10.28 % -2 % -77.65 %
Total Assets in million 216 213 199 222 227
Y / Y Net Income Change 2.75 % 40.23 % 1079450 % - -
Net Income in million 31 30 22 0 -29
Annual Return On Assets 14.38 % 14.19 % 10.84 % 0 % -12.85 %

PBYI's 5 Years Annual ROA >> Back to PBYI Management Effectiveness >> Compare PBYI ROA to its Competitors



Comment on PBYI's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 14.38 % compared to prior year, due to annual net income growth of 2.75 % to $31.11 million, while value of Puma Biotechnology Inc 's overall assets grew just by 1.39 % to $216.30 million, compared to $216.30 a year before.


More Return On Assets Ratios
PBYI's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PBYI's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PBYI's Competitors
Subscribers only: Roa for Puma Biotechnology Inc 's Suppliers
Subscribers only: Return On Assets for PBYI's Customers

You may also want to know
PBYI's Roi PBYI's Inventory Turnover Ratio PBYI's Growth Rates PBYI's Dividend Comparisons
PBYI's Profitability Ratios PBYI's Asset Turnover Ratio PBYI's Dividend Growth
PBYI's Roe PBYI's Valuation Ratios PBYI's Financial Strength Ratios PBYI's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Intuitive Surgical Inc   15.63 %
Inspire Medical Systems inc   15.21 %
Neurocrine Biosciences Inc   14.73 %
Entera Bio Ltd   14.60 %
Standard Biotools Inc   14.31 %

Date modified: 2026-09-08T21:33:08+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.